Prime Medicine (PRME) Total Liabilities (2021 - 2026)
Prime Medicine's (PRME) quarterly Total Liabilities came in at $218.0 million in Q1 2026, down 1.45% YoY from $221.2 million in Q1 2025, and down 1.73% on a QoQ basis from $221.9 million in Q4 2025.
Prime Medicine (PRME) Total Liabilities (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Total Liabilities data on file, last reported at $218.0 million in Q1 2026.
- Quarterly Total Liabilities fell 1.45% year-over-year to $218.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $218.0 million (down 1.45% YoY) and the FY2025 annual result came in at $221.9 million, up 53.69% from the prior year.
- Total Liabilities slipped to $218.0 million in Q1 2026, from $221.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $223.2 million in Q3 2025 to a low of $38.1 million in Q1 2023.
- A 5-year average of $119.5 million and a median of $67.6 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities retreated 29.3% — and 2025, when it surged 245.63%.
- Tracing PRME's Total Liabilities over 5 years: stood at $44.0 million in 2022, then jumped by 38.0% to $60.8 million in 2023, then jumped by 137.51% to $144.4 million in 2024, then jumped by 53.69% to $221.9 million in 2025, then retreated by 1.73% to $218.0 million in 2026.
- The last three Total Liabilities figures came in at $218.0 million (Q1 2026), $221.9 million (Q4 2025), and $223.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 209.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 209.23 Mn |
| Mar 31, 2026 | 218.03 Mn |
| Dec 31, 2025 | 221.87 Mn |
| Sep 30, 2025 | 223.19 Mn |
| Jun 30, 2025 | 218.15 Mn |
| Mar 31, 2025 | 221.24 Mn |
| Dec 31, 2024 | 144.36 Mn |
| Sep 30, 2024 | 143.28 Mn |
| Jun 30, 2024 | 63.12 Mn |
| Mar 31, 2024 | 67.62 Mn |
| Dec 31, 2023 | 60.78 Mn |
| Sep 30, 2023 | 45.19 Mn |
| Jun 30, 2023 | 40.76 Mn |
| Mar 31, 2023 | 38.15 Mn |
| Dec 31, 2022 | 44.04 Mn |
| Sep 30, 2022 | 42.56 Mn |
| Dec 31, 2021 | 62.30 Mn |